Cytori Therapeutics, Inc. (CYTX) Stock Price Down 2.6%
Cytori Therapeutics, Inc. (NASDAQ:CYTX) shares fell 2.6% during trading on Wednesday . The stock traded as low as $0.32 and last traded at $0.38. 294,000 shares changed hands during mid-day trading, a decline of 62% from the average session volume of 769,212 shares. The stock had previously closed at $0.39.
Several research firms recently commented on CYTX. B. Riley restated a “neutral” rating on shares of Cytori Therapeutics in a report on Sunday, July 30th. Maxim Group set a $5.00 price target on shares of Cytori Therapeutics and gave the company a “buy” rating in a report on Friday, August 11th. Zacks Investment Research lowered shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Finally, ValuEngine lowered shares of Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st.
Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. Cytori Therapeutics had a negative net margin of 271.12% and a negative return on equity of 202.43%. The company had revenue of $1.77 million during the quarter, compared to the consensus estimate of $2.04 million. During the same quarter last year, the company earned ($0.26) earnings per share. analysts predict that Cytori Therapeutics, Inc. will post -0.62 earnings per share for the current year.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Stock Ratings for Cytori Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc. and related stocks with our FREE daily email newsletter.